藥品參考
Trilaciclib
Trilaciclib is a medicine in the class oncology.
- 藥物類別: Oncology
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- 常見劑型
- 注射劑
- 常見規格
- 300 mg/20 ml
- 已知交互作用
- 28 (嚴重: 12 · 中度: 13 · 輕微: 3)
- 商品名
- 1
- 國家與市場
- 1
作用方式
Transient inhibitor of CDK 4 and 6; proliferation of hematopoietic stem and progenitor cells in bone marrow depends on CDK4/6 activity.
成人常用劑量（仿單摘要）
Decrease chemotherapy-induced myelosuppression in ES-SCLC: 240 mg/m2 as a 30-minute intravenous infusion completed no more than 4 hours before chemotherapy on each chemotherapy day; interval between doses on sequential days not greater than 28 hours
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm based on its mechanism (CDK4/6 inhibitor); no human or animal data. Pregnancy test before starting; contraception during treatment and for at least 3 weeks after the last dose.
- 哺乳
- Unsafe No data on milk levels or infant effects. Because of possible serious infant reactions, do not breastfeed during treatment and for at least 3 weeks after the last dose.
已通報的副作用
- Fatigue
- Hypocalcemia
- Hypokalemia
- Hypophosphatemia
- Increased aspartate aminotransferase
- Headache
禁忌症
- History of serious hypersensitivity reactions to trilaciclib, including anaphylaxis.
哪些人需要特別留意
- Injection-site reactions including phlebitis and thrombophlebitis; monitor, and stop infusion and permanently discontinue for severe or life-threatening reactions.
- Acute hypersensitivity reactions including facial edema, urticaria and anaphylaxis; withhold for moderate, permanently discontinue for severe or life-threatening.
- Interstitial lung disease/pneumonitis; monitor for cough, dyspnea, hypoxia and permanently discontinue for recurrent symptomatic or severe/life-threatening cases.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (28)
- Alogliptin-metformin + Trilaciclib Major
- Canagliflozin-metformin + Trilaciclib Major
- Cisplatin + Trilaciclib Major
- Dalfampridine + Trilaciclib Major
- Dapagliflozin-metformin + Trilaciclib Major
- Empagliflozin-metformin + Trilaciclib Major
- Glyburide-metformin + Trilaciclib Major
- Linagliptin-metformin + Trilaciclib Major
- Metformin + Trilaciclib Major
- Metformin-pioglitazone + Trilaciclib Major
同類別的其他藥品
常見問題
What is Trilaciclib used for?
Trilaciclib is a medicine in the class oncology.
What side effects have been reported with Trilaciclib?
Fatigue, Hypocalcemia, Hypokalemia, Hypophosphatemia, Increased aspartate aminotransferase, Headache.
Can Trilaciclib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm based on its mechanism (CDK4/6 inhibitor); no human or animal data. Pregnancy test before starting; contraception during treatment and for at least 3 weeks after the last dose. Breastfeeding: Unsafe. No data on milk levels or infant effects. Because of possible serious infant reactions, do not breastfeed during treatment and for at least 3 weeks after the last dose.
What does Trilaciclib interact with?
MediHelp lists 28 known interactions for Trilaciclib. Major: 12 · Moderate: 13 · Minor: 3. The most serious include Alogliptin-metformin, Canagliflozin-metformin, Cisplatin.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
